{"id":4511,"date":"2025-03-31T18:12:10","date_gmt":"2025-03-31T18:12:10","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/heparin-txt\/"},"modified":"2025-03-31T18:12:10","modified_gmt":"2025-03-31T18:12:10","slug":"heparin-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/heparin-txt\/","title":{"rendered":"heparin.txt"},"content":{"rendered":"

heparin <\/h1>\n

CLINICAL USE <\/H3>
\nAnticoagulant

DOSE IN NORMAL RENAL FUNCTION <\/H3>Treatment of deep vein thrombosis and pulmonary embolism:IV: Loading dose: 5000\u201310 000 units \u2014then a continuous intravenous infusion of 18 units\/kg\/hourTreatment of deep vein thrombosis: SC: 15 000 units every 12 hours, dose \u2014is adjusted according to laboratory monitoringProphylaxis: 5000 units every 8\u201312 hours or according to local protocols

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :3000\u201340 000<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :>90<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 0 (up to 50% after large doses)<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.06\u20130.1<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :1\u20136\/Slightly prolonged (half-life increases with dose)

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Not dialysed. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Analgesics: increased risk of bleeding with NSAIDs \u2013 avoid concomitant use with IV diclofenac; increased risk of haemorrhage with ketorolac \u2013 avoid concomitant use\n
  • Nitrates: anticoagulant effect reduced by infusions of glyceryl trinitrateDrotrecogin alfa: manufacturer advises to avoid use of high doses of heparin with drotrecogin alfaUse with care in patients receiving oral anticoagulants, platelet aggregation inhibitors, aspirin or dextran

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>

    IV infusion <\/H4> or bolus, SC

    Rate of Administration <\/H4>18 units\/kg\/hour, or according to local protocol

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Half-life is slightly prolonged in haemodialysis patients after intravenous administrationAlso used for the maintenance of extracorporeal circuits in cardiopulmonary bypass and haemodialysis1 mg protamine is required to neutralise 100 IU heparin; give slowly over 10 minutes, and do not exceed a total dose of 50 mgTo reduce or prevent fibrin formation in patients on PD, heparin may be added to PD fluid at a concentration of 1000 IU\/L.
    \n","protected":false},"excerpt":{"rendered":"

    heparin CLINICAL USE Anticoagulant DOSE IN NORMAL RENAL FUNCTION Treatment<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4511","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4511","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4511"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4511\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4511"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4511"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}